ONO Pharmaceutical Co. Ltd.

02/08/2024 | Press release | Distributed by Public on 02/07/2024 20:03

Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in[...]

 This material is intended to notify the press release issued on February 7 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click https://www.bms.com/media/press-releases.html for the original press release.